Delpor is a biotechnology company developing drug delivery technologies to transport proteins, peptides, and small molecules.
Delpor, Inc. engages in developing and acquiring drug delivery technologies that enable the sustained or pattern specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant. Its technologies include Prozor, which is used for the delivery of antipsychotics and other small molecule drugs from a non-mechanical implantable drug delivery device; NANOPOR, a non-mechanical implantable drug delivery device in which sustained release is provided by membrane architecture; and Delos PUMP, a self-contained and electro-osmotically driven implantable drug delivery device to deliver drugs in predetermined patterns. The company was incorporated in 2009 and is based in San Francisco, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 16, 2021 | Grant | $2.50M | 1 | National Institutes of Health | — | Detail |
Mar 28, 2016 | Series A | $1M | 1 | — | — | Detail |
Oct 3, 2013 | Debt Financing | $470K | — | — | — | Detail |
Jun 16, 2010 | Series Unknown | $0.90M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Institutes of Health | Yes | Grant |
Kairos Ventures | — | Series A |